Translation from unconventional 5' start sites drives tumour initiation.

TitleTranslation from unconventional 5' start sites drives tumour initiation.
Publication TypeJournal Article
Year of Publication2017
AuthorsSendoel A, Dunn JG, Rodriguez EH, Naik S, Gomez NC, Hurwitz B, Levorse J, Dill BD, Schramek D, Molina H, Weissman JS, Fuchs E
JournalNature
Volume541
Issue7638
Pagination494-499
Date Published2017 01 26
ISSN1476-4687
Keywords5' Untranslated Regions, Animals, Carcinogenesis, Carcinoma, Squamous Cell, Disease Models, Animal, Disease Progression, Epidermis, Eukaryotic Initiation Factor-2, Female, Humans, Keratinocytes, Male, Mice, Oncogenes, Open Reading Frames, Peptide Chain Initiation, Translational, Precancerous Conditions, Prognosis, Ribosomes, RNA Interference, RNA, Messenger, Skin Neoplasms, SOXB1 Transcription Factors
Abstract

We are just beginning to understand how translational control affects tumour initiation and malignancy. Here we use an epidermis-specific, in vivo ribosome profiling strategy to investigate the translational landscape during the transition from normal homeostasis to malignancy. Using a mouse model of inducible SOX2, which is broadly expressed in oncogenic RAS-associated cancers, we show that despite widespread reductions in translation and protein synthesis, certain oncogenic mRNAs are spared. During tumour initiation, the translational apparatus is redirected towards unconventional upstream initiation sites, enhancing the translational efficiency of oncogenic mRNAs. An in vivo RNA interference screen of translational regulators revealed that depletion of conventional eIF2 complexes has adverse effects on normal but not oncogenic growth. Conversely, the alternative initiation factor eIF2A is essential for cancer progression, during which it mediates initiation at these upstream sites, differentially skewing translation and protein expression. Our findings unveil a role for the translation of 5' untranslated regions in cancer, and expose new targets for therapeutic intervention.

DOI10.1038/nature21036
Alternate JournalNature
PubMed ID28077873
PubMed Central IDPMC5287289
Grant ListR37 AR027883 / AR / NIAMS NIH HHS / United States
T32 GM007618 / GM / NIGMS NIH HHS / United States
T32 GM007739 / GM / NIGMS NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States

Person Type: